肝康合剂加减治疗原发性肝癌74例中医疗效分析

目的：观察肝康合剂加减治疗原发性肝癌患者的中医疗效。方法：采用病例自身前后对照的方法,以肝康合剂加减治疗原发性肝癌患者74例,每日1剂,6个月为1个疗程。观察患者不同中医症状出现频率、生存期及治疗前后中医症状、体征的变化。结果：患者治疗前以脾虚的症状出现频率为最高,患者的生存期为（26.93±21.69）月,74例原发性肝癌患者有表现的症状、体征共有84个,症状消失率≥95%的症状数12个,症状消失率≥70%的症状数33个,症状消失率≥30%的症状数为10个。结论：肝康合剂可提高患者生存期,明显改善患者症状体征,提高患者的生存质量。

Clinical Study on Effect of Gankang Composition in treating 74 Patients with Primary Liver Cancer

Objective：To observe the efficacy of Gankang Composition in treating patients with primary liver cancer（PLC）.Methods：Autonomous Control Study was used.The 74 patients with PLC were treated by Gankang composition,one dose once daily,Patients were treated for 6 months.Survival stage,frequency of occurrence of symptoms and physical signs and the changes of symptoms and physical signs before and after treatment in patients were observed.Results：Survival stage in patinets were（26.93±21.69） months.Patients with PLC had 84 symptoms and physical signs.Syndrome of spleen deficiency is the highest.Disappearance rate of symptoms were different after treatment.Conclusion Survival stage and life quality of patients were increased by Gankang Composition.Clinical symptoms and physical signs in patients were improved significantly after treatment.